1. Volume 150, Issue 7, Pages 1590-1598 (June 2016)
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease 
Paul J. Pockros, K. Rajender Reddy, Parvez S. Mantry, Eric Cohen, Michael Bennett, Mark S. Sulkowski, David E. Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz 
Gastroenterology 
Volume 150, Issue 7, Pages (June 2016)
DOI: /j.gastro
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Hemoglobin levels for patients interrupting RBV. Nine patients interrupted RBV due to hemoglobin declines. Plotted are individual patient hemoglobin levels over time for 6 patients; plots for the remaining 3 patients are located in Supplementary Figure 2. Ribavirin was resumed in 3 patients (B, D, and E). Blue-filled symbols indicate RBV administration. Black-filled symbols indicate when RBV was interrupted. Red-filled symbols indicate administration of erythropoietin. Open symbols indicate hemoglobin levels during the post-treatment period. The horizontal dotted line demarcates 10 g/dL. BL, baseline; EOT, end of treatment; PTW, post-treatment week.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
Mean plasma trough concentrations for study drugs. Individual patients' plasma drug trough concentrations are plotted using a binned time interval of >22–26 hours for PTV, RTV, and OBV, and an interval of >10–14 hours for DSV, DSV M1, and RBV. Horizontal lines and the table indicate the geometric mean in ng/mL; whiskers indicate 95% confidence intervals. DSV M1, dasabuvir principal metabolite; CV, coefficient of variation.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions